nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—ALB—Acitretin—psoriasis	0.0593	0.0759	CbGbCtD
Enzalutamide—CYP2C8—Tazarotene—psoriasis	0.0579	0.0742	CbGbCtD
Enzalutamide—CYP3A5—Beclomethasone—psoriasis	0.056	0.0717	CbGbCtD
Enzalutamide—CYP2B6—Cholecalciferol—psoriasis	0.0327	0.0418	CbGbCtD
Enzalutamide—ALB—Mycophenolate mofetil—psoriasis	0.0277	0.0355	CbGbCtD
Enzalutamide—CYP2D6—Hydroxyurea—psoriasis	0.026	0.0333	CbGbCtD
Enzalutamide—CYP2C8—Cholecalciferol—psoriasis	0.0247	0.0317	CbGbCtD
Enzalutamide—CYP3A5—Mycophenolate mofetil—psoriasis	0.0223	0.0286	CbGbCtD
Enzalutamide—ALB—Prednisone—psoriasis	0.0222	0.0284	CbGbCtD
Enzalutamide—CYP2C8—Mycophenolate mofetil—psoriasis	0.0214	0.0275	CbGbCtD
Enzalutamide—CYP2C19—Cholecalciferol—psoriasis	0.0207	0.0266	CbGbCtD
Enzalutamide—CYP3A4—Calcitriol—psoriasis	0.0195	0.0249	CbGbCtD
Enzalutamide—CYP3A5—Hydrocortisone—psoriasis	0.0179	0.0229	CbGbCtD
Enzalutamide—CYP2C9—Cholecalciferol—psoriasis	0.0172	0.0221	CbGbCtD
Enzalutamide—CYP2C8—Hydrocortisone—psoriasis	0.0172	0.022	CbGbCtD
Enzalutamide—CYP3A5—Cyclosporine—psoriasis	0.0169	0.0216	CbGbCtD
Enzalutamide—CYP2C8—Cyclosporine—psoriasis	0.0162	0.0208	CbGbCtD
Enzalutamide—CYP2D6—Cholecalciferol—psoriasis	0.0158	0.0202	CbGbCtD
Enzalutamide—CYP3A4—Methoxsalen—psoriasis	0.0151	0.0194	CbGbCtD
Enzalutamide—ABCB1—Mycophenolate mofetil—psoriasis	0.0145	0.0186	CbGbCtD
Enzalutamide—CYP2C19—Prednisone—psoriasis	0.0144	0.0184	CbGbCtD
Enzalutamide—CYP2B6—Dexamethasone—psoriasis	0.0141	0.0181	CbGbCtD
Enzalutamide—CYP2C19—Cyclosporine—psoriasis	0.0136	0.0175	CbGbCtD
Enzalutamide—ABCB1—Betamethasone—psoriasis	0.0125	0.0159	CbGbCtD
Enzalutamide—ABCB1—Prednisolone—psoriasis	0.0123	0.0157	CbGbCtD
Enzalutamide—ABCB1—Hydrocortisone—psoriasis	0.0116	0.0149	CbGbCtD
Enzalutamide—ABCB1—Prednisone—psoriasis	0.0116	0.0149	CbGbCtD
Enzalutamide—CYP2C9—Cyclosporine—psoriasis	0.0113	0.0145	CbGbCtD
Enzalutamide—CYP3A5—Dexamethasone—psoriasis	0.0111	0.0143	CbGbCtD
Enzalutamide—ALB—Methotrexate—psoriasis	0.0111	0.0143	CbGbCtD
Enzalutamide—ABCB1—Cyclosporine—psoriasis	0.011	0.0141	CbGbCtD
Enzalutamide—CYP2C8—Dexamethasone—psoriasis	0.0107	0.0137	CbGbCtD
Enzalutamide—CYP2D6—Cyclosporine—psoriasis	0.0104	0.0133	CbGbCtD
Enzalutamide—CYP3A4—Cholecalciferol—psoriasis	0.01	0.0128	CbGbCtD
Enzalutamide—CYP2C19—Dexamethasone—psoriasis	0.00898	0.0115	CbGbCtD
Enzalutamide—CYP3A4—Mycophenolate mofetil—psoriasis	0.0087	0.0111	CbGbCtD
Enzalutamide—CYP3A4—Triamcinolone—psoriasis	0.0087	0.0111	CbGbCtD
Enzalutamide—CYP2C9—Dexamethasone—psoriasis	0.00746	0.00956	CbGbCtD
Enzalutamide—CYP3A4—Betamethasone—psoriasis	0.00746	0.00955	CbGbCtD
Enzalutamide—CYP3A4—Prednisolone—psoriasis	0.00736	0.00943	CbGbCtD
Enzalutamide—ABCB1—Dexamethasone—psoriasis	0.00724	0.00928	CbGbCtD
Enzalutamide—CYP3A4—Hydrocortisone—psoriasis	0.00698	0.00894	CbGbCtD
Enzalutamide—CYP3A4—Prednisone—psoriasis	0.00695	0.0089	CbGbCtD
Enzalutamide—CYP2D6—Dexamethasone—psoriasis	0.00682	0.00874	CbGbCtD
Enzalutamide—CYP3A4—Cyclosporine—psoriasis	0.00659	0.00844	CbGbCtD
Enzalutamide—ABCB1—Methotrexate—psoriasis	0.00582	0.00745	CbGbCtD
Enzalutamide—CYP3A4—Dexamethasone—psoriasis	0.00434	0.00556	CbGbCtD
Enzalutamide—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00233	0.0457	CbGpPWpGaD
Enzalutamide—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00197	0.0387	CbGpPWpGaD
Enzalutamide—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00176	0.0345	CbGpPWpGaD
Enzalutamide—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00162	0.0318	CbGpPWpGaD
Enzalutamide—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00161	0.0315	CbGpPWpGaD
Enzalutamide—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00151	0.0296	CbGpPWpGaD
Enzalutamide—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00145	0.0283	CbGpPWpGaD
Enzalutamide—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00141	0.0277	CbGpPWpGaD
Enzalutamide—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00122	0.024	CbGpPWpGaD
Enzalutamide—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00109	0.0214	CbGpPWpGaD
Enzalutamide—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.001	0.0197	CbGpPWpGaD
Enzalutamide—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000996	0.0195	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL22—psoriasis	0.000856	0.0168	CbGpPWpGaD
Enzalutamide—AR—Coregulation of Androgen receptor activity—ZMIZ1—psoriasis	0.000813	0.0159	CbGpPWpGaD
Enzalutamide—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000657	0.0129	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—ZMIZ1—psoriasis	0.000601	0.0118	CbGpPWpGaD
Enzalutamide—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.0006	0.0118	CbGpPWpGaD
Enzalutamide—AR—Regulation of Androgen receptor activity—REL—psoriasis	0.000595	0.0116	CbGpPWpGaD
Enzalutamide—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000592	0.0116	CbGpPWpGaD
Enzalutamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000587	0.0115	CbGpPWpGaD
Enzalutamide—AR—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000586	0.0115	CbGpPWpGaD
Enzalutamide—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000579	0.0113	CbGpPWpGaD
Enzalutamide—AR—Coregulation of Androgen receptor activity—CARM1—psoriasis	0.000524	0.0103	CbGpPWpGaD
Enzalutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000508	0.00995	CbGpPWpGaD
Enzalutamide—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000502	0.00982	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000491	0.00961	CbGpPWpGaD
Enzalutamide—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000487	0.00953	CbGpPWpGaD
Enzalutamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000476	0.00932	CbGpPWpGaD
Enzalutamide—AR—Nuclear Receptors—VDR—psoriasis	0.000457	0.00894	CbGpPWpGaD
Enzalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000454	0.00889	CbGpPWpGaD
Enzalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000448	0.00877	CbGpPWpGaD
Enzalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000417	0.00817	CbGpPWpGaD
Enzalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000414	0.0081	CbGpPWpGaD
Enzalutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000412	0.00807	CbGpPWpGaD
Enzalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000412	0.00806	CbGpPWpGaD
Enzalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000408	0.008	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000393	0.00771	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—CARM1—psoriasis	0.000387	0.00758	CbGpPWpGaD
Enzalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000368	0.0072	CbGpPWpGaD
Enzalutamide—AR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000361	0.00707	CbGpPWpGaD
Enzalutamide—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000358	0.007	CbGpPWpGaD
Enzalutamide—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000354	0.00694	CbGpPWpGaD
Enzalutamide—Injury—Prednisone—psoriasis	0.00034	0.00202	CcSEcCtD
Enzalutamide—Haematuria—Mycophenolate mofetil—psoriasis	0.000339	0.00202	CcSEcCtD
Enzalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000338	0.00662	CbGpPWpGaD
Enzalutamide—Upper respiratory tract infection—Hydrocortisone—psoriasis	0.000338	0.00201	CcSEcCtD
Enzalutamide—Nervous system disorder—Hydroxyurea—psoriasis	0.000336	0.002	CcSEcCtD
Enzalutamide—Diarrhoea—Calcitriol—psoriasis	0.000336	0.002	CcSEcCtD
Enzalutamide—Thrombocytopenia—Hydroxyurea—psoriasis	0.000336	0.002	CcSEcCtD
Enzalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000335	0.00657	CbGpPWpGaD
Enzalutamide—Epistaxis—Mycophenolate mofetil—psoriasis	0.000335	0.002	CcSEcCtD
Enzalutamide—Sinusitis—Mycophenolate mofetil—psoriasis	0.000334	0.00198	CcSEcCtD
Enzalutamide—Skin disorder—Hydroxyurea—psoriasis	0.000333	0.00198	CcSEcCtD
Enzalutamide—Amnesia—Prednisone—psoriasis	0.000333	0.00198	CcSEcCtD
Enzalutamide—Dry skin—Dexamethasone—psoriasis	0.000329	0.00196	CcSEcCtD
Enzalutamide—Dry skin—Betamethasone—psoriasis	0.000329	0.00196	CcSEcCtD
Enzalutamide—Bronchitis—Triamcinolone—psoriasis	0.000329	0.00196	CcSEcCtD
Enzalutamide—Rhinitis—Cyclosporine—psoriasis	0.000328	0.00195	CcSEcCtD
Enzalutamide—Hypoaesthesia—Cyclosporine—psoriasis	0.000325	0.00194	CcSEcCtD
Enzalutamide—Pharyngitis—Cyclosporine—psoriasis	0.000325	0.00193	CcSEcCtD
Enzalutamide—Infestation—Hydrocortisone—psoriasis	0.000324	0.00193	CcSEcCtD
Enzalutamide—Infestation NOS—Hydrocortisone—psoriasis	0.000324	0.00193	CcSEcCtD
Enzalutamide—Urinary tract disorder—Cyclosporine—psoriasis	0.000323	0.00192	CcSEcCtD
Enzalutamide—Connective tissue disorder—Cyclosporine—psoriasis	0.000321	0.00191	CcSEcCtD
Enzalutamide—Urethral disorder—Cyclosporine—psoriasis	0.000321	0.00191	CcSEcCtD
Enzalutamide—Rhinitis—Mycophenolate mofetil—psoriasis	0.00032	0.0019	CcSEcCtD
Enzalutamide—AR—Nuclear Receptors—PPARG—psoriasis	0.000318	0.00623	CbGpPWpGaD
Enzalutamide—Upper respiratory tract infection—Triamcinolone—psoriasis	0.000318	0.00189	CcSEcCtD
Enzalutamide—Hypoaesthesia—Mycophenolate mofetil—psoriasis	0.000318	0.00189	CcSEcCtD
Enzalutamide—Pharyngitis—Mycophenolate mofetil—psoriasis	0.000317	0.00188	CcSEcCtD
Enzalutamide—Muscular weakness—Dexamethasone—psoriasis	0.000317	0.00188	CcSEcCtD
Enzalutamide—Muscular weakness—Betamethasone—psoriasis	0.000317	0.00188	CcSEcCtD
Enzalutamide—Vertigo—Mycophenolic acid—psoriasis	0.000316	0.00188	CcSEcCtD
Enzalutamide—Urinary tract disorder—Mycophenolate mofetil—psoriasis	0.000315	0.00188	CcSEcCtD
Enzalutamide—Leukopenia—Mycophenolic acid—psoriasis	0.000315	0.00188	CcSEcCtD
Enzalutamide—Oedema peripheral—Mycophenolate mofetil—psoriasis	0.000314	0.00187	CcSEcCtD
Enzalutamide—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.000314	0.00187	CcSEcCtD
Enzalutamide—Asthenia—Acitretin—psoriasis	0.000313	0.00187	CcSEcCtD
Enzalutamide—Urethral disorder—Mycophenolate mofetil—psoriasis	0.000313	0.00186	CcSEcCtD
Enzalutamide—Sepsis—Methotrexate—psoriasis	0.000312	0.00186	CcSEcCtD
Enzalutamide—Pruritus—Acitretin—psoriasis	0.000309	0.00184	CcSEcCtD
Enzalutamide—Pruritus—Fluocinolone Acetonide—psoriasis	0.000308	0.00183	CcSEcCtD
Enzalutamide—Headache—Calcitriol—psoriasis	0.000308	0.00183	CcSEcCtD
Enzalutamide—Convulsion—Mycophenolic acid—psoriasis	0.000305	0.00182	CcSEcCtD
Enzalutamide—Hypertension—Mycophenolic acid—psoriasis	0.000304	0.00181	CcSEcCtD
Enzalutamide—Arthralgia—Mycophenolic acid—psoriasis	0.0003	0.00178	CcSEcCtD
Enzalutamide—Diarrhoea—Acitretin—psoriasis	0.000299	0.00178	CcSEcCtD
Enzalutamide—Anxiety—Mycophenolic acid—psoriasis	0.000299	0.00178	CcSEcCtD
Enzalutamide—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000298	0.00177	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000298	0.00177	CcSEcCtD
Enzalutamide—Angiopathy—Cyclosporine—psoriasis	0.000297	0.00177	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000296	0.00176	CcSEcCtD
Enzalutamide—Fatigue—Hydroxyurea—psoriasis	0.000296	0.00176	CcSEcCtD
Enzalutamide—AR—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000291	0.00569	CbGpPWpGaD
Enzalutamide—Angiopathy—Mycophenolate mofetil—psoriasis	0.00029	0.00172	CcSEcCtD
Enzalutamide—Dizziness—Acitretin—psoriasis	0.000289	0.00172	CcSEcCtD
Enzalutamide—Dizziness—Fluocinolone Acetonide—psoriasis	0.000288	0.00171	CcSEcCtD
Enzalutamide—Epistaxis—Triamcinolone—psoriasis	0.000288	0.00171	CcSEcCtD
Enzalutamide—Dry skin—Prednisone—psoriasis	0.000287	0.00171	CcSEcCtD
Enzalutamide—Mental disorder—Cyclosporine—psoriasis	0.000287	0.00171	CcSEcCtD
Enzalutamide—Connective tissue disorder—Hydrocortisone—psoriasis	0.000286	0.0017	CcSEcCtD
Enzalutamide—Infection—Mycophenolic acid—psoriasis	0.000285	0.0017	CcSEcCtD
Enzalutamide—Nervous system disorder—Mycophenolic acid—psoriasis	0.000282	0.00168	CcSEcCtD
Enzalutamide—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000281	0.00167	CcSEcCtD
Enzalutamide—Mental disorder—Mycophenolate mofetil—psoriasis	0.00028	0.00166	CcSEcCtD
Enzalutamide—Skin disorder—Mycophenolic acid—psoriasis	0.000279	0.00166	CcSEcCtD
Enzalutamide—Muscular weakness—Prednisone—psoriasis	0.000276	0.00164	CcSEcCtD
Enzalutamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000276	0.0054	CbGpPWpGaD
Enzalutamide—Rhinitis—Triamcinolone—psoriasis	0.000274	0.00163	CcSEcCtD
Enzalutamide—Headache—Acitretin—psoriasis	0.000274	0.00163	CcSEcCtD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000273	0.00535	CbGpPWpGaD
Enzalutamide—Headache—Fluocinolone Acetonide—psoriasis	0.000273	0.00162	CcSEcCtD
Enzalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000273	0.00534	CbGpPWpGaD
Enzalutamide—Pharyngitis—Triamcinolone—psoriasis	0.000272	0.00162	CcSEcCtD
Enzalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000269	0.00527	CbGpPWpGaD
Enzalutamide—Back pain—Mycophenolate mofetil—psoriasis	0.000269	0.0016	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000262	0.00156	CcSEcCtD
Enzalutamide—Insomnia—Mycophenolic acid—psoriasis	0.00026	0.00155	CcSEcCtD
Enzalutamide—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000259	0.00506	CbGpPWpGaD
Enzalutamide—Paraesthesia—Mycophenolic acid—psoriasis	0.000258	0.00154	CcSEcCtD
Enzalutamide—Vertigo—Cyclosporine—psoriasis	0.000256	0.00152	CcSEcCtD
Enzalutamide—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000255	0.00499	CbGpPWpGaD
Enzalutamide—Leukopenia—Cyclosporine—psoriasis	0.000255	0.00152	CcSEcCtD
Enzalutamide—Mental disorder—Hydrocortisone—psoriasis	0.000255	0.00152	CcSEcCtD
Enzalutamide—Neutropenia—Prednisone—psoriasis	0.000253	0.0015	CcSEcCtD
Enzalutamide—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000253	0.00495	CbGpPWpGaD
Enzalutamide—AR—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000252	0.00493	CbGpPWpGaD
Enzalutamide—Vertigo—Mycophenolate mofetil—psoriasis	0.00025	0.00149	CcSEcCtD
Enzalutamide—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000249	0.00488	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.000249	0.00488	CbGpPWpGaD
Enzalutamide—Leukopenia—Mycophenolate mofetil—psoriasis	0.000249	0.00148	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000248	0.00148	CcSEcCtD
Enzalutamide—Fatigue—Mycophenolic acid—psoriasis	0.000248	0.00147	CcSEcCtD
Enzalutamide—Convulsion—Cyclosporine—psoriasis	0.000247	0.00147	CcSEcCtD
Enzalutamide—Asthenia—Hydroxyurea—psoriasis	0.000246	0.00146	CcSEcCtD
Enzalutamide—Hypertension—Cyclosporine—psoriasis	0.000246	0.00146	CcSEcCtD
Enzalutamide—Arthralgia—Cyclosporine—psoriasis	0.000242	0.00144	CcSEcCtD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000242	0.00475	CbGpPWpGaD
Enzalutamide—Anxiety—Cyclosporine—psoriasis	0.000242	0.00144	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000241	0.00143	CcSEcCtD
Enzalutamide—Convulsion—Mycophenolate mofetil—psoriasis	0.000241	0.00143	CcSEcCtD
Enzalutamide—Hypertension—Mycophenolate mofetil—psoriasis	0.00024	0.00143	CcSEcCtD
Enzalutamide—Arthralgia—Mycophenolate mofetil—psoriasis	0.000237	0.00141	CcSEcCtD
Enzalutamide—Anxiety—Mycophenolate mofetil—psoriasis	0.000236	0.0014	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000235	0.0014	CcSEcCtD
Enzalutamide—Diarrhoea—Hydroxyurea—psoriasis	0.000235	0.0014	CcSEcCtD
Enzalutamide—Vertigo—Prednisolone—psoriasis	0.000233	0.00139	CcSEcCtD
Enzalutamide—Infection—Cyclosporine—psoriasis	0.000231	0.00137	CcSEcCtD
Enzalutamide—Back pain—Triamcinolone—psoriasis	0.000231	0.00137	CcSEcCtD
Enzalutamide—AR—SIDS Susceptibility Pathways—IL13—psoriasis	0.000229	0.00449	CbGpPWpGaD
Enzalutamide—Nervous system disorder—Cyclosporine—psoriasis	0.000228	0.00136	CcSEcCtD
Enzalutamide—Thrombocytopenia—Cyclosporine—psoriasis	0.000228	0.00135	CcSEcCtD
Enzalutamide—Vertigo—Hydrocortisone—psoriasis	0.000227	0.00135	CcSEcCtD
Enzalutamide—Dizziness—Hydroxyurea—psoriasis	0.000227	0.00135	CcSEcCtD
Enzalutamide—Skin disorder—Cyclosporine—psoriasis	0.000226	0.00134	CcSEcCtD
Enzalutamide—Angiopathy—Betamethasone—psoriasis	0.000225	0.00134	CcSEcCtD
Enzalutamide—Angiopathy—Dexamethasone—psoriasis	0.000225	0.00134	CcSEcCtD
Enzalutamide—Infection—Mycophenolate mofetil—psoriasis	0.000225	0.00134	CcSEcCtD
Enzalutamide—Convulsion—Prednisolone—psoriasis	0.000225	0.00134	CcSEcCtD
Enzalutamide—Hypertension—Prednisolone—psoriasis	0.000224	0.00133	CcSEcCtD
Enzalutamide—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000222	0.00132	CcSEcCtD
Enzalutamide—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000222	0.00132	CcSEcCtD
Enzalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000221	0.00433	CbGpPWpGaD
Enzalutamide—Skin disorder—Mycophenolate mofetil—psoriasis	0.00022	0.00131	CcSEcCtD
Enzalutamide—Convulsion—Hydrocortisone—psoriasis	0.000219	0.0013	CcSEcCtD
Enzalutamide—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000219	0.00429	CbGpPWpGaD
Enzalutamide—Hypertension—Hydrocortisone—psoriasis	0.000219	0.0013	CcSEcCtD
Enzalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000218	0.00427	CbGpPWpGaD
Enzalutamide—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000216	0.00423	CbGpPWpGaD
Enzalutamide—Headache—Hydroxyurea—psoriasis	0.000215	0.00128	CcSEcCtD
Enzalutamide—Anxiety—Hydrocortisone—psoriasis	0.000215	0.00128	CcSEcCtD
Enzalutamide—Vertigo—Triamcinolone—psoriasis	0.000214	0.00127	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000214	0.00127	CcSEcCtD
Enzalutamide—AR—Notch-mediated HES/HEY network—CD4—psoriasis	0.000213	0.00417	CbGpPWpGaD
Enzalutamide—Connective tissue disorder—Prednisone—psoriasis	0.000213	0.00127	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000212	0.00126	CcSEcCtD
Enzalutamide—Neutropenia—Methotrexate—psoriasis	0.000211	0.00126	CcSEcCtD
Enzalutamide—Insomnia—Cyclosporine—psoriasis	0.00021	0.00125	CcSEcCtD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.00021	0.00411	CbGpPWpGaD
Enzalutamide—Upper respiratory tract infection—Methotrexate—psoriasis	0.00021	0.00125	CcSEcCtD
Enzalutamide—Paraesthesia—Cyclosporine—psoriasis	0.000209	0.00124	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000207	0.00123	CcSEcCtD
Enzalutamide—Convulsion—Triamcinolone—psoriasis	0.000206	0.00123	CcSEcCtD
Enzalutamide—Asthenia—Mycophenolic acid—psoriasis	0.000206	0.00123	CcSEcCtD
Enzalutamide—Hypertension—Triamcinolone—psoriasis	0.000206	0.00122	CcSEcCtD
Enzalutamide—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000205	0.00402	CbGpPWpGaD
Enzalutamide—Infection—Hydrocortisone—psoriasis	0.000205	0.00122	CcSEcCtD
Enzalutamide—Insomnia—Mycophenolate mofetil—psoriasis	0.000205	0.00122	CcSEcCtD
Enzalutamide—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000204	0.00121	CcSEcCtD
Enzalutamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000203	0.00398	CbGpPWpGaD
Enzalutamide—Pruritus—Mycophenolic acid—psoriasis	0.000203	0.00121	CcSEcCtD
Enzalutamide—Nervous system disorder—Hydrocortisone—psoriasis	0.000203	0.00121	CcSEcCtD
Enzalutamide—Pneumonia—Methotrexate—psoriasis	0.000203	0.00121	CcSEcCtD
Enzalutamide—Infestation NOS—Methotrexate—psoriasis	0.000201	0.0012	CcSEcCtD
Enzalutamide—Infestation—Methotrexate—psoriasis	0.000201	0.0012	CcSEcCtD
Enzalutamide—AR—FOXA1 transcription factor network—JUN—psoriasis	0.000201	0.00393	CbGpPWpGaD
Enzalutamide—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000201	0.00119	CcSEcCtD
Enzalutamide—Skin disorder—Hydrocortisone—psoriasis	0.000201	0.00119	CcSEcCtD
Enzalutamide—Fatigue—Cyclosporine—psoriasis	0.0002	0.00119	CcSEcCtD
Enzalutamide—Diarrhoea—Mycophenolic acid—psoriasis	0.000197	0.00117	CcSEcCtD
Enzalutamide—Angiopathy—Prednisone—psoriasis	0.000196	0.00117	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000196	0.00116	CcSEcCtD
Enzalutamide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000195	0.00383	CbGpPWpGaD
Enzalutamide—Vertigo—Dexamethasone—psoriasis	0.000194	0.00116	CcSEcCtD
Enzalutamide—Vertigo—Betamethasone—psoriasis	0.000194	0.00116	CcSEcCtD
Enzalutamide—Infection—Triamcinolone—psoriasis	0.000193	0.00115	CcSEcCtD
Enzalutamide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000193	0.00377	CbGpPWpGaD
Enzalutamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000192	0.00377	CbGpPWpGaD
Enzalutamide—Haematuria—Methotrexate—psoriasis	0.000192	0.00114	CcSEcCtD
Enzalutamide—Insomnia—Prednisolone—psoriasis	0.000191	0.00114	CcSEcCtD
Enzalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00019	0.00372	CbGpPWpGaD
Enzalutamide—Dizziness—Mycophenolic acid—psoriasis	0.00019	0.00113	CcSEcCtD
Enzalutamide—Epistaxis—Methotrexate—psoriasis	0.00019	0.00113	CcSEcCtD
Enzalutamide—Paraesthesia—Prednisolone—psoriasis	0.00019	0.00113	CcSEcCtD
Enzalutamide—Mental disorder—Prednisone—psoriasis	0.00019	0.00113	CcSEcCtD
Enzalutamide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000189	0.00371	CbGpPWpGaD
Enzalutamide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000188	0.00112	CcSEcCtD
Enzalutamide—Convulsion—Dexamethasone—psoriasis	0.000187	0.00111	CcSEcCtD
Enzalutamide—Convulsion—Betamethasone—psoriasis	0.000187	0.00111	CcSEcCtD
Enzalutamide—Insomnia—Hydrocortisone—psoriasis	0.000187	0.00111	CcSEcCtD
Enzalutamide—Hypertension—Dexamethasone—psoriasis	0.000187	0.00111	CcSEcCtD
Enzalutamide—Hypertension—Betamethasone—psoriasis	0.000187	0.00111	CcSEcCtD
Enzalutamide—Paraesthesia—Hydrocortisone—psoriasis	0.000185	0.0011	CcSEcCtD
Enzalutamide—Anxiety—Betamethasone—psoriasis	0.000183	0.00109	CcSEcCtD
Enzalutamide—Anxiety—Dexamethasone—psoriasis	0.000183	0.00109	CcSEcCtD
Enzalutamide—Headache—Mycophenolic acid—psoriasis	0.00018	0.00107	CcSEcCtD
Enzalutamide—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.00018	0.00352	CbGpPWpGaD
Enzalutamide—Pharyngitis—Methotrexate—psoriasis	0.000179	0.00107	CcSEcCtD
Enzalutamide—Urinary tract disorder—Methotrexate—psoriasis	0.000179	0.00106	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000178	0.00106	CcSEcCtD
Enzalutamide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000178	0.00349	CbGpPWpGaD
Enzalutamide—Fatigue—Hydrocortisone—psoriasis	0.000178	0.00106	CcSEcCtD
Enzalutamide—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000177	0.00347	CbGpPWpGaD
Enzalutamide—Urethral disorder—Methotrexate—psoriasis	0.000177	0.00105	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000177	0.00105	CcSEcCtD
Enzalutamide—Insomnia—Triamcinolone—psoriasis	0.000176	0.00105	CcSEcCtD
Enzalutamide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000176	0.00344	CbGpPWpGaD
Enzalutamide—Infection—Dexamethasone—psoriasis	0.000175	0.00104	CcSEcCtD
Enzalutamide—Infection—Betamethasone—psoriasis	0.000175	0.00104	CcSEcCtD
Enzalutamide—Paraesthesia—Triamcinolone—psoriasis	0.000175	0.00104	CcSEcCtD
Enzalutamide—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000174	0.00341	CbGpPWpGaD
Enzalutamide—Nervous system disorder—Betamethasone—psoriasis	0.000173	0.00103	CcSEcCtD
Enzalutamide—Nervous system disorder—Dexamethasone—psoriasis	0.000173	0.00103	CcSEcCtD
Enzalutamide—AR—Regulation of Androgen receptor activity—JUN—psoriasis	0.000173	0.00339	CbGpPWpGaD
Enzalutamide—Thrombocytopenia—Betamethasone—psoriasis	0.000173	0.00103	CcSEcCtD
Enzalutamide—Thrombocytopenia—Dexamethasone—psoriasis	0.000173	0.00103	CcSEcCtD
Enzalutamide—Vertigo—Prednisone—psoriasis	0.000169	0.00101	CcSEcCtD
Enzalutamide—Fatigue—Triamcinolone—psoriasis	0.000168	0.000998	CcSEcCtD
Enzalutamide—ALB—Hemostasis—SERPINB8—psoriasis	0.000168	0.00328	CbGpPWpGaD
Enzalutamide—Asthenia—Cyclosporine—psoriasis	0.000167	0.000992	CcSEcCtD
Enzalutamide—AR—Notch-mediated HES/HEY network—STAT3—psoriasis	0.000165	0.00323	CbGpPWpGaD
Enzalutamide—Pruritus—Cyclosporine—psoriasis	0.000164	0.000979	CcSEcCtD
Enzalutamide—Angiopathy—Methotrexate—psoriasis	0.000164	0.000976	CcSEcCtD
Enzalutamide—Convulsion—Prednisone—psoriasis	0.000163	0.000971	CcSEcCtD
Enzalutamide—Asthenia—Mycophenolate mofetil—psoriasis	0.000163	0.000968	CcSEcCtD
Enzalutamide—Hypertension—Prednisone—psoriasis	0.000163	0.000968	CcSEcCtD
Enzalutamide—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000162	0.00318	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL13—psoriasis	0.000161	0.00316	CbGpPWpGaD
Enzalutamide—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000161	0.000957	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000161	0.000957	CcSEcCtD
Enzalutamide—Pruritus—Mycophenolate mofetil—psoriasis	0.00016	0.000955	CcSEcCtD
Enzalutamide—Arthralgia—Prednisone—psoriasis	0.00016	0.000954	CcSEcCtD
Enzalutamide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	0.00016	0.00313	CbGpPWpGaD
Enzalutamide—Anxiety—Prednisone—psoriasis	0.00016	0.000951	CcSEcCtD
Enzalutamide—AR—Gene Expression—TARS—psoriasis	0.00016	0.00313	CbGpPWpGaD
Enzalutamide—Insomnia—Dexamethasone—psoriasis	0.00016	0.00095	CcSEcCtD
Enzalutamide—Insomnia—Betamethasone—psoriasis	0.00016	0.00095	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000159	0.000948	CcSEcCtD
Enzalutamide—Diarrhoea—Cyclosporine—psoriasis	0.000159	0.000946	CcSEcCtD
Enzalutamide—Paraesthesia—Dexamethasone—psoriasis	0.000158	0.000943	CcSEcCtD
Enzalutamide—Paraesthesia—Betamethasone—psoriasis	0.000158	0.000943	CcSEcCtD
Enzalutamide—Mental disorder—Methotrexate—psoriasis	0.000158	0.000943	CcSEcCtD
Enzalutamide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000155	0.000923	CcSEcCtD
Enzalutamide—Dizziness—Cyclosporine—psoriasis	0.000154	0.000915	CcSEcCtD
Enzalutamide—Infection—Prednisone—psoriasis	0.000153	0.000909	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000152	0.000907	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Betamethasone—psoriasis	0.000152	0.000907	CcSEcCtD
Enzalutamide—Back pain—Methotrexate—psoriasis	0.000152	0.000906	CcSEcCtD
Enzalutamide—Fatigue—Dexamethasone—psoriasis	0.000152	0.000905	CcSEcCtD
Enzalutamide—Fatigue—Betamethasone—psoriasis	0.000152	0.000905	CcSEcCtD
Enzalutamide—Nervous system disorder—Prednisone—psoriasis	0.000151	0.000897	CcSEcCtD
Enzalutamide—Dizziness—Mycophenolate mofetil—psoriasis	0.00015	0.000892	CcSEcCtD
Enzalutamide—Skin disorder—Prednisone—psoriasis	0.000149	0.000888	CcSEcCtD
Enzalutamide—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000148	0.0029	CbGpPWpGaD
Enzalutamide—Asthenia—Hydrocortisone—psoriasis	0.000148	0.000882	CcSEcCtD
Enzalutamide—Pruritus—Hydrocortisone—psoriasis	0.000146	0.00087	CcSEcCtD
Enzalutamide—Headache—Cyclosporine—psoriasis	0.000146	0.000867	CcSEcCtD
Enzalutamide—AR—SIDS Susceptibility Pathways—IL10—psoriasis	0.000143	0.00281	CbGpPWpGaD
Enzalutamide—Headache—Mycophenolate mofetil—psoriasis	0.000142	0.000845	CcSEcCtD
Enzalutamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000142	0.00278	CbGpPWpGaD
Enzalutamide—Vertigo—Methotrexate—psoriasis	0.000141	0.000841	CcSEcCtD
Enzalutamide—Diarrhoea—Hydrocortisone—psoriasis	0.000141	0.000841	CcSEcCtD
Enzalutamide—Leukopenia—Methotrexate—psoriasis	0.000141	0.000838	CcSEcCtD
Enzalutamide—ALB—Folate Metabolism—CAT—psoriasis	0.000141	0.00275	CbGpPWpGaD
Enzalutamide—Musculoskeletal discomfort—Prednisone—psoriasis	0.00014	0.000833	CcSEcCtD
Enzalutamide—Dizziness—Prednisolone—psoriasis	0.00014	0.000832	CcSEcCtD
Enzalutamide—Asthenia—Triamcinolone—psoriasis	0.00014	0.00083	CcSEcCtD
Enzalutamide—Insomnia—Prednisone—psoriasis	0.000139	0.000827	CcSEcCtD
Enzalutamide—Paraesthesia—Prednisone—psoriasis	0.000138	0.000821	CcSEcCtD
Enzalutamide—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000138	0.0027	CbGpPWpGaD
Enzalutamide—Pruritus—Triamcinolone—psoriasis	0.000138	0.000819	CcSEcCtD
Enzalutamide—ALB—Vitamin B12 Metabolism—CRP—psoriasis	0.000137	0.00269	CbGpPWpGaD
Enzalutamide—Dizziness—Hydrocortisone—psoriasis	0.000137	0.000813	CcSEcCtD
Enzalutamide—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	0.000136	0.00267	CbGpPWpGaD
Enzalutamide—Convulsion—Methotrexate—psoriasis	0.000136	0.000811	CcSEcCtD
Enzalutamide—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000135	0.00264	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—APOE—psoriasis	0.000134	0.00263	CbGpPWpGaD
Enzalutamide—Arthralgia—Methotrexate—psoriasis	0.000134	0.000797	CcSEcCtD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	0.000134	0.00262	CbGpPWpGaD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000133	0.000792	CcSEcCtD
Enzalutamide—Fatigue—Prednisone—psoriasis	0.000132	0.000789	CcSEcCtD
Enzalutamide—Headache—Prednisolone—psoriasis	0.000132	0.000788	CcSEcCtD
Enzalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000132	0.00259	CbGpPWpGaD
Enzalutamide—Headache—Hydrocortisone—psoriasis	0.000129	0.00077	CcSEcCtD
Enzalutamide—ALB—Folate Metabolism—IL4—psoriasis	0.000129	0.00253	CbGpPWpGaD
Enzalutamide—Dizziness—Triamcinolone—psoriasis	0.000129	0.000765	CcSEcCtD
Enzalutamide—Infection—Methotrexate—psoriasis	0.000128	0.000759	CcSEcCtD
Enzalutamide—Asthenia—Betamethasone—psoriasis	0.000127	0.000754	CcSEcCtD
Enzalutamide—Asthenia—Dexamethasone—psoriasis	0.000127	0.000754	CcSEcCtD
Enzalutamide—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	0.000126	0.00247	CbGpPWpGaD
Enzalutamide—Nervous system disorder—Methotrexate—psoriasis	0.000126	0.00075	CcSEcCtD
Enzalutamide—Thrombocytopenia—Methotrexate—psoriasis	0.000126	0.000748	CcSEcCtD
Enzalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000125	0.00245	CbGpPWpGaD
Enzalutamide—Pruritus—Dexamethasone—psoriasis	0.000125	0.000743	CcSEcCtD
Enzalutamide—Pruritus—Betamethasone—psoriasis	0.000125	0.000743	CcSEcCtD
Enzalutamide—Skin disorder—Methotrexate—psoriasis	0.000125	0.000742	CcSEcCtD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	0.000124	0.00244	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	0.000123	0.00241	CbGpPWpGaD
Enzalutamide—Headache—Triamcinolone—psoriasis	0.000122	0.000725	CcSEcCtD
Enzalutamide—Diarrhoea—Dexamethasone—psoriasis	0.000121	0.000719	CcSEcCtD
Enzalutamide—Diarrhoea—Betamethasone—psoriasis	0.000121	0.000719	CcSEcCtD
Enzalutamide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000117	0.0023	CbGpPWpGaD
Enzalutamide—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000117	0.000696	CcSEcCtD
Enzalutamide—Dizziness—Betamethasone—psoriasis	0.000117	0.000694	CcSEcCtD
Enzalutamide—Dizziness—Dexamethasone—psoriasis	0.000117	0.000694	CcSEcCtD
Enzalutamide—Insomnia—Methotrexate—psoriasis	0.000116	0.000691	CcSEcCtD
Enzalutamide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000116	0.00227	CbGpPWpGaD
Enzalutamide—Paraesthesia—Methotrexate—psoriasis	0.000115	0.000686	CcSEcCtD
Enzalutamide—AR—Androgen receptor signaling pathway—JUN—psoriasis	0.000114	0.00224	CbGpPWpGaD
Enzalutamide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000113	0.00221	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—CAT—psoriasis	0.000112	0.00219	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—CRP—psoriasis	0.000112	0.00219	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000111	0.00218	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000111	0.00218	CbGpPWpGaD
Enzalutamide—Gastrointestinal disorder—Methotrexate—psoriasis	0.000111	0.00066	CcSEcCtD
Enzalutamide—Fatigue—Methotrexate—psoriasis	0.000111	0.000659	CcSEcCtD
Enzalutamide—Headache—Betamethasone—psoriasis	0.000111	0.000658	CcSEcCtD
Enzalutamide—Headache—Dexamethasone—psoriasis	0.000111	0.000658	CcSEcCtD
Enzalutamide—Asthenia—Prednisone—psoriasis	0.00011	0.000656	CcSEcCtD
Enzalutamide—Pruritus—Prednisone—psoriasis	0.000109	0.000647	CcSEcCtD
Enzalutamide—Diarrhoea—Prednisone—psoriasis	0.000105	0.000626	CcSEcCtD
Enzalutamide—AR—Generic Transcription Pathway—CARM1—psoriasis	0.000104	0.00204	CbGpPWpGaD
Enzalutamide—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000104	0.00203	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—ICAM1—psoriasis	0.000103	0.00201	CbGpPWpGaD
Enzalutamide—Dizziness—Prednisone—psoriasis	0.000102	0.000605	CcSEcCtD
Enzalutamide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000101	0.00199	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL10—psoriasis	0.000101	0.00197	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—STAT3—psoriasis	9.89e-05	0.00194	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL4—psoriasis	9.81e-05	0.00192	CbGpPWpGaD
Enzalutamide—Headache—Prednisone—psoriasis	9.63e-05	0.000573	CcSEcCtD
Enzalutamide—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	9.6e-05	0.00188	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-B—psoriasis	9.59e-05	0.00188	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	9.58e-05	0.00188	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	9.36e-05	0.00183	CbGpPWpGaD
Enzalutamide—Asthenia—Methotrexate—psoriasis	9.22e-05	0.000548	CcSEcCtD
Enzalutamide—Pruritus—Methotrexate—psoriasis	9.09e-05	0.000541	CcSEcCtD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	8.92e-05	0.00175	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-A—psoriasis	8.88e-05	0.00174	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—CRP—psoriasis	8.87e-05	0.00174	CbGpPWpGaD
Enzalutamide—Diarrhoea—Methotrexate—psoriasis	8.79e-05	0.000523	CcSEcCtD
Enzalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.74e-05	0.00171	CbGpPWpGaD
Enzalutamide—Dizziness—Methotrexate—psoriasis	8.49e-05	0.000505	CcSEcCtD
Enzalutamide—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	8.15e-05	0.0016	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	8.12e-05	0.00159	CbGpPWpGaD
Enzalutamide—Headache—Methotrexate—psoriasis	8.05e-05	0.000479	CcSEcCtD
Enzalutamide—ALB—SLC-mediated transmembrane transport—CP—psoriasis	8e-05	0.00157	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	7.99e-05	0.00156	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.85e-05	0.00154	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—IFNG—psoriasis	7.81e-05	0.00153	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—JUN—psoriasis	7.49e-05	0.00147	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—JUN—psoriasis	7.29e-05	0.00143	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	7.21e-05	0.00141	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.02e-05	0.00138	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	6.54e-05	0.00128	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—NFKB1—psoriasis	6.5e-05	0.00127	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.37e-05	0.00125	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—VDR—psoriasis	6.23e-05	0.00122	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—TNF—psoriasis	6.21e-05	0.00122	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—IFNG—psoriasis	6.21e-05	0.00122	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	6.2e-05	0.00121	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.97e-05	0.00117	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IFNG—psoriasis	5.93e-05	0.00116	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.92e-05	0.00116	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—CXCL8—psoriasis	5.51e-05	0.00108	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—TNF—psoriasis	5.46e-05	0.00107	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	5.42e-05	0.00106	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—NDUFA5—psoriasis	5.2e-05	0.00102	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.17e-05	0.00101	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	5.16e-05	0.00101	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—NDUFA5—psoriasis	5.08e-05	0.000995	CbGpPWpGaD
Enzalutamide—ALB—Platelet degranulation—VEGFA—psoriasis	5.06e-05	0.00099	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—TNF—psoriasis	5.06e-05	0.00099	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—CARM1—psoriasis	5.02e-05	0.000984	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—IL6—psoriasis	5.01e-05	0.000982	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—TP53—psoriasis	4.94e-05	0.000968	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—ITGAL—psoriasis	4.87e-05	0.000953	CbGpPWpGaD
Enzalutamide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	4.82e-05	0.000944	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.64e-05	0.00091	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.54e-05	0.000889	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.48e-05	0.000877	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—TP53—psoriasis	4.46e-05	0.000873	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CYP2S1—psoriasis	4.42e-05	0.000866	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—IL6—psoriasis	4.41e-05	0.000863	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NDUFA5—psoriasis	4.4e-05	0.000862	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NDUFA5—psoriasis	4.38e-05	0.000857	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—PPARG—psoriasis	4.34e-05	0.000851	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CYP2S1—psoriasis	4.32e-05	0.000846	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.1e-05	0.000804	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.09e-05	0.000802	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.08e-05	0.000799	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—IL6—psoriasis	4.08e-05	0.000799	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—CP—psoriasis	4.07e-05	0.000797	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—TNF—psoriasis	4.02e-05	0.000787	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NDUFA5—psoriasis	3.93e-05	0.00077	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	3.88e-05	0.00076	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—TNF—psoriasis	3.84e-05	0.000751	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NDUFA5—psoriasis	3.84e-05	0.000751	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.81e-05	0.000747	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CYP2S1—psoriasis	3.74e-05	0.000733	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CYP2S1—psoriasis	3.72e-05	0.000729	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.66e-05	0.000718	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NDUFA5—psoriasis	3.61e-05	0.000708	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NDUFA5—psoriasis	3.58e-05	0.000702	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.56e-05	0.000698	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.4e-05	0.000666	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CYP2S1—psoriasis	3.34e-05	0.000654	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.34e-05	0.000654	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CYP2S1—psoriasis	3.26e-05	0.000639	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—IL6—psoriasis	3.24e-05	0.000635	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CYP2S1—psoriasis	3.07e-05	0.000602	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CYP2S1—psoriasis	3.05e-05	0.000597	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—VDR—psoriasis	3e-05	0.000588	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.53e-05	0.000495	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.43e-05	0.000477	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NDUFA5—psoriasis	2.36e-05	0.000463	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.24e-05	0.000439	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.21e-05	0.000433	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CARM1—psoriasis	2.16e-05	0.000423	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CARM1—psoriasis	2.11e-05	0.000413	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—PPARG—psoriasis	2.09e-05	0.00041	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CYP2S1—psoriasis	2.01e-05	0.000393	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—NOS2—psoriasis	2e-05	0.000391	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.96e-05	0.000384	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.95e-05	0.000382	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.89e-05	0.000371	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CARM1—psoriasis	1.83e-05	0.000358	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CARM1—psoriasis	1.82e-05	0.000356	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.75e-05	0.000343	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.71e-05	0.000335	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.7e-05	0.000333	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.67e-05	0.000327	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CARM1—psoriasis	1.63e-05	0.00032	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.6e-05	0.000313	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CARM1—psoriasis	1.59e-05	0.000312	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.53e-05	0.000299	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CARM1—psoriasis	1.5e-05	0.000294	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CARM1—psoriasis	1.49e-05	0.000291	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.39e-05	0.000272	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CAT—psoriasis	1.33e-05	0.00026	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CAT—psoriasis	1.3e-05	0.000254	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—VEGFA—psoriasis	1.16e-05	0.000226	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CAT—psoriasis	1.12e-05	0.00022	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CAT—psoriasis	1.12e-05	0.000219	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—APOE—psoriasis	1.03e-05	0.000202	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—APOE—psoriasis	1.01e-05	0.000198	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CAT—psoriasis	1e-05	0.000197	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CARM1—psoriasis	9.81e-06	0.000192	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CAT—psoriasis	9.8e-06	0.000192	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CAT—psoriasis	9.23e-06	0.000181	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CAT—psoriasis	9.15e-06	0.000179	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PPARG—psoriasis	8.99e-06	0.000176	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PPARG—psoriasis	8.79e-06	0.000172	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TP53—psoriasis	8.74e-06	0.000171	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—APOE—psoriasis	8.74e-06	0.000171	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—APOE—psoriasis	8.69e-06	0.00017	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—APOE—psoriasis	7.8e-06	0.000153	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—APOE—psoriasis	7.61e-06	0.000149	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PPARG—psoriasis	7.61e-06	0.000149	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PPARG—psoriasis	7.57e-06	0.000148	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—APOE—psoriasis	7.17e-06	0.00014	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—APOE—psoriasis	7.11e-06	0.000139	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PPARG—psoriasis	6.79e-06	0.000133	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PPARG—psoriasis	6.63e-06	0.00013	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PPARG—psoriasis	6.25e-06	0.000122	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PPARG—psoriasis	6.19e-06	0.000121	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CAT—psoriasis	6.03e-06	0.000118	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—APOE—psoriasis	4.69e-06	9.18e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PPARG—psoriasis	4.08e-06	8e-05	CbGpPWpGaD
